Please assess the completion status of the following clinical trial:

Trial Title: Compensatory Reserve Index (CRI) for Management of COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Eligible patients will be those who are:~* COVID-19 positive;~* Ages \> 18 and \< 70 years old;~* Require \> 2 liters of oxygen by nasal cannula to maintain SpO2 \> 90%;~* Are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service).~Exclusion Criteria:~* COVID-19 negative~* Age \<18 or \>70 years~* On \<2 liters oxygen via nasal canula~* Pregnant~* Incarcerated~* DNR/DNI~* Decisionally Challenged

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CRI Monitoring/Management (Type: None): These patients are COVID-19 positive; ages \> 18 and \< 70 years old; require \> 2 liters of oxygen by nasal cannula to maintain SpO2 \> 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). Patients in the study cohort will also be monitored with a CipherOx CR T1 tablet in a continuous manner to determine if maintaining CRI vales between 0.9-0.7 will: 1) help guide IV fluid (e.g. crystalloid, colloids, blood products) and medication therapy (e.g. diuretics); 2) allows earlier identification of patients who are poorly compensating and will require ICU level care; 3) reduces AKI and/or need for CRRT; and 4) improves clinical outcomes.

Based on this trial design, predict the completion outcome and termination type (if applicable).